期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

放射性核素显像在心肌病诊治中的临床应用 被引量：2

Clinical application of radionuclide imaging in the diagnosis and therapy of cardiomyopathy
下载PDF
导出
摘要 心肌病是指伴有心肌功能障碍的心肌疾病。根据病理生理学可分为4型，即肥厚型心肌病（HCM）、扩张型心肌病（DCM）、限制性心肌病（RCM）以及致心律失常型右室心肌病（ARVD／C）。其中HCM与DCM在临床中较为常见。HCM的发病率大约为1／500^[1-2]，而DCM的发病率为13／10万～84／10万不等^[3]。目前HCM与DCM的发病病因及致病机理尚不确切明了。
作者 孙牧川 李娜 李亚明
机构地区 中国医科大学附属第一医院核医学科
出处 《中国临床医学影像杂志》 CAS 北大核心 2008年第9期658-660,共3页 Journal of China Clinic Medical Imaging
关键词 心肌疾病 放射性核素显像
分类号 R542.2 [医药卫生—心血管疾病] R817.4 [医药卫生—影像医学与核医学]
  • 相关文献

参考文献29

  • 1Sherrid MV. Pathophysiology and treatment of hypertrophic cardiomyopathy[J]. Prog Cardiovasc Dis, 2006, 49(2): 123-151.
  • 2Robert R, Ulrich S. Current concepts of the pathogenesis and treatment of hypertrophic cardiomyopathy [J]. Circulation, 2005, 112: 293-296.
  • 3Keng FY, Chang SM, Cwajg E, et al. Gated SPECT in patients with hypertrophic obstructive cardiomyopathy undergoing transcoronary ethanol septal ablation [J]. J Nucl Cardiol, 2002, 9 (6): 594-600.
  • 4Matsuo S, Sato Y, Nakae I, et al. Evaluation of cardiac resynchronization therapy in drug-resistant dilated-phase hypertrophic cardiomyopathy by means of Tc-99m sestamibi ECG-gated SPECT[J]. Ann Nucl Med, 2006, 20(9): 643-647.
  • 5Nagueh SF, Mahmarian JJ. Noninvasive cardiac imaging in patients with hypertrophic cardiomyopathy [J]. J Am Coil Cardiol, 2006, 48(12): 2410-2422.
  • 6Cecchi F, Olivotto I, Gistri R, et al. Coronary microvascular dysfunction and prognosis in hypertrophic cardiomyopathy[J]. N Engl J Med, 2003, 349: 1027-1035.
  • 7Sorajja P, Chareonthaitawee P, Ommen SR, et al. Prognostic utility of single-photon emission computed tomography in adult patients with hypertrophic cardiomyopathy [J]. Am Heart J, 2006, 151(2): 426-435.
  • 8Romero-Farina G, Candell-Riera J, Galve E, et al. Do myocardial perfusion SPECT and radionuclide angiography studies in adult patients with hypertrophic cardiomyopathy have prognostic implications?[J]. J Nucl Cardiol, 2004, 11(5): 578-586.
  • 9Buyukdereli G, Kanadasi M, Kibar M. Washout rates of ^99mTctetrofosmin in asymmetric septal hypertrophy [J]. Ann Nucl Med, 2005, 19(1): 29-33.
  • 10Lwin TT, Takeda T, Wu J, et al. Enhanced washout of ^99mTctetrofosmin in hypertrophic cardiomyopathy: quantitative comparisons with regional ^123I-BMIPP uptake and wall thickness determined by MRI [J]. Eur J Nucl Med Mol Imaging, 2003, 30(7): 966-973.

二级参考文献9

  • 1Perry E. Diagnosis and management of dilated cardiomyopathy. Heart,2000, 84: 106-112.
  • 2于维汉.心肌疾病.见:叶任高,主编.内科学.第5版.北京:人民卫生出版社,2002.345-34.
  • 3Arbustini E, Diegoli M, Fasani R, et al. Mitochondrial DNA mutations and mitochondrial abnormalities in dilated cardiomyopathy. Am J Pathol,1998, 153: 1501-1510.
  • 4Diana J, Josefina O, Antoni B, et al. Mitochondrial function in heart muscle from patients with idiopathic dilated cardiomyopathy. Cardiovas Res,2000, 45: 860-865.
  • 5Biray C, George AB. Are 99Tcm labeled myocardial peffusion agents adequate for detection of myocardial viability? Clin Cardiol, 1998, 21: 235-242.
  • 6Pattl C, Robert L, Stuart H, et al. Effect of mitochondrial viability and metabolism on 99Tcm-sestamibi myocardial retention. Eur J Nucl Med,1993, 20: 20-25.
  • 7三上雄路,桑原洋一,木下敬彦,他.机能低下心筋における99Tcm-MIBIの洗ぃ出しの检讨.核医学,2001,38:609-610.
  • 8Wolf S, Michael C, Diefer C, et al. Washout and redistribution between immediate and two-hour myocardial images using 99Tcm-sestamibi. Eur J Nucl Med, 1995, 22: 49-55.
  • 9Maja F, Jean G, Robert E, et al. Myocardial clearance of 99Tcm hexakis2-methoxy-2-methylpropyl isonittile (MIBI) in patients with coronary artery disease. Clin Nucl Med, 1990, 15: 307-312.

共引文献3

同被引文献9

引证文献2

二级引证文献8

中国临床医学影像杂志
2008年 第9期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部